In this article:

BTIG Thinks AKOUOS’s Stock is Going to Recover

In this article:
In this article:

BTIG analyst Robert Hazlett reiterated a Buy rating on AKOUOS (AKUSResearch Report) yesterday and set a price target of $35.00. The company’s shares closed last Wednesday at $6.02, close to its 52-week low of $5.30.

According to TipRanks.com, Hazlett is a 3-star analyst with an average return of 3.1% and a 32.6% success rate. Hazlett covers the Healthcare sector, focusing on stocks such as Eiger Biopharmaceuticals, Syndax Pharmaceuticals, and TRACON Pharmaceuticals.

AKOUOS has an analyst consensus of Moderate Buy, with a price target consensus of $30.00, representing a 419.0% upside. In a report issued on February 7, H.C. Wainwright also reiterated a Buy rating on the stock with a $25.00 price target.

See the top stocks recommended by analysts >>

Based on AKOUOS’s latest earnings release for the quarter ending September 30, the company reported a quarterly GAAP net loss of $22.91 million. In comparison, last year the company had a GAAP net loss of $13.09 million.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Akouos Inc is a genetic medicine company focused on developing gene therapies that restore, improve, and preserve hearing. The company is involved in developing potential genetic medicines for a variety of inner ear disorders.

Read More on AKUS:

Tired of arriving late to the Big Returns Party?​
Most investors don’t have major gainers like TSLA or NVDA on their radar from the start.
The profusion of opinions on social media and financial blogs makes it impossible to distinguish between real growth potential and pure hype.
​​For the past decade, we have developed and perfected technology designed to help private investors, just like you, find the best opportunities, with the greatest upside potential, in any financial climate.​
Learn More

Latest News Feed

In this article:

Latest News Feed